Elevated expression of TCF3 was linked to better outcomes in the overall cohort (HR = 0.75,P  = 0.00068) and in bladder cancer (HR = 0.49,P  = 0.018) and urothelial cancer (HR = 0.76,P  = 0.056) patients, while glioblastoma (HR = 12.22,P  < 0.001) and melanoma (HR = 1.38,P  = 0.048) were the opposite. This evidence concerns the gene TCF3 and melanoma.